Miriam Longo

A novel gene signature to diagnose MASLD in metabolically unhealthy obese individuals.

M. Maggioni, S. Badiali, P. Dongiovanni, 2023, Biochemical pharmacology.

https://doi.org/10.1194/jlr.P090449 PCSK7 gene variation bridges atherogenic dyslipidemia with hepatic inflammation in NAFLD contains a supplement. patient-oriented

L. Valenti, S. Fargion, G. Baselli, 2019 .

NR1H4 rs35724 G>C Variant Modulates Liver Damage in Nonalcoholic Fatty Liver Disease

L. N. Valenti, J. Pihlajamäki, H. Yki-Järvinen, 2020, SSRN Electronic Journal.

DGAT1 and DGAT2 Inhibitors for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Management: Benefits for Their Single or Combined Application

M. Meroni, E. Paolini, Miriam Longo, 2024, International journal of molecular sciences.

Cardiometabolic risk factors in MASLD patients with HCC: the other side of the coin

P. Dongiovanni, M. Meroni, Miriam Longo, 2024, Frontiers in endocrinology.